NCT05292196终止2 期
A Randomized, Double-blind, Placebo-parallel, Multicenter Phase II Trial of the Efficacy and Safety of TQC3721 Suspension for Inhalation in the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 59
- 试验地点
- 11
- 主要终点
- The peak of Forced Expiratory Volume(FEV1)
研究概览
简要总结
TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects. This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 Sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the test;
- •2 Capable of using the study nebulizer correctly and complying with all study restrictions and procedures;
- •3 Aged between 18 and 75 years old, both men and women;
- •4 Body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value) and body weight is ≥45kg;
- •5 Subjects have no pregnancy plan and have voluntarily taken effective contraceptive measures for at least 1 month after being screened to the last use of the study drug;
- •6 12-lead electrocardiogram with QT interval corrected ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no morphologic and other clinical significant abnormalities that the investigator considered inappropriate for the study;
- •7 Ability to perform acceptable and reproducible spirometry;
- •8 Patients previously treated with LAMA or LABA who had evidence of stable use for at least 3 months prior to screening and agreed to continue use during the study period;
- •9 Capable of withholding LAMA or LABA（ Twice-Daily maintenance LAMA or LABA for at least 24 hours and Once-Daily maintenance LAMA or LABA for at least 48 hours) and SAMA、SABAs（at least 4 hours）prior to initiation of any spirometry;
- •10 According to the 2020 GOLD Guidelines, Post-bronchodilator spirometry at screening must demonstrate FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥30 % to ≤80% of predicted normal;
- •11 Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years, former cigarette smokers should stop smoke at least 6 months before visit 1).
排除标准
- •1 Intolerance to salbutamol or this product.
- •2 ≥1 hospitalization for COPD treatment within 6 months prior to screening.
- •3 Antibiotic treatment for lower respiratory tract infection within 3 months prior to screening.
- •4 Use of prohibited medications within the time intervals.
- •5 Patients who were currently diagnosed with asthma, active tuberculosis, lung cancer and other active lung diseases and were considered unsuitable for the study.
- •6 Previous lung resection or lung reduction surgery.
- •7 Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study.
- •8 A history of drug or alcohol abuse in the past 3 years (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).
- •9 Have participated in a clinical trial within one month prior to screening or within 5 half-lives of the investigational drug, whichever is the longer.
- •10 Women who are breast-feeding.
- •11 A history of myocardial infarction, congestive heart failure, and unstable or uncontrolled hypertension (systolic blood pressure ≥160mmHg and diastolic blood pressure ≥100mmHg after drug control) within 6 months prior to screening.
- •12 History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
- •13 Alanine aminotransferase (ALT) or aspartate aminotransferase(AST)≥ 2 x upper limit of normal (ULN), or other abnormal test results were deemed unsuitable for inclusion by the investigator.
- •14 Required use of oxygen therapy, even on an occasional basis.
- •15 Other conditions that the investigator considered inappropriate for participation in the study.
研究组 & 干预措施
TQC3721 suspension for inhalation
Experimental
TQC3721 suspension for inhalation, four weeks as a treatment cycle.
干预措施: TQC3721 suspension for inhalation (Drug)
TQC3721 suspension placebo for inhalation
Placebo Comparator
TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
干预措施: TQC3721 suspension placebo for inhalation (Drug)
结局指标
主要结局
The peak of Forced Expiratory Volume(FEV1)
时间窗: From the enrollment of the subjects to four weeks after administration
Change of the maximum value of FEV1 was determined from baseline to 30minute, 1hour, 2hour and 3hour after medication at week four
次要结局
- Morning trough FEV1(From the enrollment of the subjects to four weeks after administration)
- COPD Assessment Test (CAT)(From enrollment to four weeks after administration)
- Incidence of adverse events associated with the study drug(from baseline to four weeks after administration)
- Rescue medication(From baseline to four weeks after administration)
- Number of adverse events related to the study drug(from baseline to four weeks after administration)
- Average FEV1(From the enrollment of the subjects to four weeks after administration)
- Incidence of adverse events(from baseline to four weeks after administration)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT06527144Chia Tai Tianqing Pharmaceutical Group Co., Ltd.240
Unknown
2 期
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT03986073Chia Tai Tianqing Pharmaceutical Group Co., Ltd.120
已完成
2 期
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.Chronic Obstructive Pulmonary DiseaseNCT05987371Chia Tai Tianqing Pharmaceutical Group Co., Ltd.75
Unknown
1 期
A Clinical Trial of TQC3721 Suspension for InhalationChronic Obstructive Pulmonary DiseaseNCT05051930Chia Tai Tianqing Pharmaceutical Group Co., Ltd.114
Unknown
1 期
TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerNonsmall-cell Lung CancerNCT05284994Chia Tai Tianqing Pharmaceutical Group Co., Ltd.160